San Diego, CA (December 15, 2017) – January Therapeutics, Inc., a biotechnology company discovering and developing novel nanoparticle therapeutics announced the appointment of two new members to its board of directors. David Mizrachi will serve as a shareholder representative, and Dr. Michael Hostetler will serve as an independent board member. These two appointments expand the board to five members from three.
David Mizrachi has a distinguished career in business. He is currently Sr. Vice President Global Business Development and is a member of the corporate executive committee at Standard Textile, a private vertically integrated technology-based textile company with worldwide operations.
Dr. Michael Hostetler provides strategic intellectual property counseling to life science companies. He is a partner in the intellectual property practice at Wilson Sonsini Goodrich & Rosati.
“We are excited to have both Mike and David join our board, and look forward to their insights and extensive experience” said Robin Jackman, Chief Executive Officer of January Therapeutics. “We have made significant advances on our lead program while finding equally important advances in some new and unexpected directions. We look forward to continued success with Mike and David’s contributions.”
About January Therapeutics, Inc.
January Therapeutics is a biotechnology company focusing on discovery of novel cancer therapeutics that leverage the proven clinical benefits of albumin nanoparticle formulations. Building upon the finding that albumin nano-formulations drive substantial improvements in the efficacy of known drugs, the company’s goal is to create novel drugs with superior efficacy and reduced toxicity in hard-to-treat malignancies. Initial applications are in advanced pancreatic, lung, and ovarian cancers. January Therapeutics was founded in 2016 and is located in San Diego, CA